| References: |
Description of Alisertib (MLN8237): MLN8237 is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers, including colon and breast cancers. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
For the detailed information about the solubility of MLN8237 (Alisertib) in water, the solubility of MLN8237 (Alisertib) in DMSO, the solubility of MLN8237 (Alisertib) in PBS buffer, the animal experiment（test） of MLN8237 (Alisertib),the in vivo,in vitro and clinical trial test of MLN8237 (Alisertib),the cell experiment（test） of MLN8237 (Alisertib),the IC50, EC50 and Affinity of MLN8237 (Alisertib), please contact DC Chemicals. |
